オクヤマ　リョウ   OKUYAMA Ryo   奥山 亮    所属   立命館アジア太平洋大学  国際経営学部    職種   教授
言語種別	英語
発行・発表の年月	2024/02
形態種別	学術論文
査読	査読あり
標題	Increased contribution of small companies to late-entry drugs: a changing trend in FDA-approved drugs during the 2020s.
執筆形態	単著
掲載誌名	Drug Discovery Today
掲載区分	国外
巻・号・頁	29(2),pp.103866
担当区分	筆頭著者,責任著者
著者・共著者	Ryo Okuyama
概要	Small- and medium-sized enterprises (SMEs) have significantly boosted innovative drug discovery, whereas large pharmaceutical companies have focused on incremental drug innovation. I explored the evolving role of SMEs in late-entry drug discovery. A comparative analysis of new drugs approved by the US Food and Drug Administration (FDA) during the 2020s with those approved previously revealed that SMEs have expanded their role to late-entry drug discovery while maintaining their contribution to first-in-target drug discovery. I analyzed the characteristics of SMEs responsible for the discovery of late-entry drugs approved during the 2020s, and the modality, market entry timing, and differentiation points of the drugs. I also discuss encompassing opportunities for SMEs, pharmaceutical industry future alliance strategies, and the importance of startup promotion measures.
DOI	https://doi.org/10.1016/j.drudis.2023.103866